Longitudinal humoral immune response against COVID-19 adenovirus-based vaccines in patients with multiple sclerosis from Argentina undergoing immunosuppressive treatment

被引：0

作者：

Silva, B. A. ^{[1
,2
,3
]}

Miglietta, E. ^{[2
]}

Eizaguirre, B. ^{[1
]}

Alonso, R. ^{[1
]}

Wenker, S. ^{[2
]}

Casabona, J. C. ^{[2
]}

Casas, M. ^{[1
]}

Lazaro, L. ^{[1
]}

Cohen, L. ^{[1
]}

Pita, C. ^{[1
]}

Man, F. ^{[4
]}

Portuondo, G. ^{[4
]}

Bisso, A. Lopez ^{[4
]}

Zabala, N. ^{[4
]}

Casales, F. ^{[5
]}

Imhoff, G. ^{[6
]}

Steinberg, J. ^{[6
]}

Lopez, P. ^{[7
]}

Contentti, E. Carnero ^{[7
]}

Deri, N. ^{[8
]}

Sinay, V. ^{[9
]}

Hryb, J. ^{[10
]}

Chiganer, E. ^{[10
]}

Leguizamon, F. ^{[11
]}

Tkachuk, V. ^{[12
]}

Bauer, J. ^{[13
]}

Giachello, S. ^{[14
]}

Henestroza, P. ^{[14
]}

Garcea, O. ^{[1
]}

Vinzon, S. ^{[15
]}

Podhajcer, O. ^{[15
]}

Pitossi, F. ^{[2
]}

Ferrari, C. ^{[2
]}

机构：

[1] Hosp Ramos Mejia, Ctr Univ Esclerosis Multiple, Buenos Aires, Argentina

[2] Leloir Inst Fdn, Lab Terapias Regenerat Protectoras Sistema, Buenos Aires, Argentina

[3] Hosp Italiano Buenos Aires, Secc Enfermedades Desmielinizantes, Buenos Aires, DF, Argentina

[4] Hosp Ramos Mejia, Serv Neurol, Buenos Aires, DF, Argentina

[5] Sanatorio Arcos, Serv Neurol, Buenos Aires, Argentina

[6] Hosp Britanico, Serv Neuro, Buenos Aires, Argentina

[7] Hosp Aleman, Unidad Neuroinmunol, Buenos Aires, Argentina

[8] DIABAID, Buenos Aires, Argentina

[9] Fdn Favaloro, Buenos Aires, Argentina

[10] Hosp Durand, Consult Neuroinmunol Clin, Buenos Aires, Argentina

[11] Hosp Alvarez, Buenos Aires, Argentina

[12] Hosp Clin Buenos Aires, Clin Enfermedades Desmielinizantes, Buenos Aires, Argentina

[13] Esclerosis Multiple Argentina, Buenos Aires, Argentina

[14] Asociac Lucha Esclerosis Multiple, San Antonio, Argentina

[15] Leloir Inst Fdn, Lab Terapia Mol & Celular, Buenos Aires, Argentina

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EP1094

引用

页码：868 / 868

页数：1

共 50 条

[31] Serological effect of mRNA vaccination against COVID-19 in multiple sclerosis patients treated with immunosuppressive DMTs
Mazziotti, V.
Crescenzo, F.
Tamanti, A.
Ziccardi, S.
Guandalini, M.
Dapor, C.
Colombi, A.
Camera, V.
Peloso, A.
Colato, E.
Pisani, A. I.
Pezzini, F.
Marastoni, D.
Turano, E.
Calabrese, M.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 644 - 645
[32] Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients
Torgauten, Hilde M.
Onyango, Therese Bredholt
Ljostveit, Sonja
Hallin, Erik I.
Serkland, Trond T.
Skrede, Silje
Langeland, Nina
Cox, Rebecca Jane
Wergeland, Stig
Myhr, Kjell-Morten
Torkildsen, Oivind
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 89
[33] Long-Term Immune Response to COVID-19 Vaccines in Multiple Sclerosis: A Multi-Center Study
David-Porada, Julia
Xia, Zongqi
Tozlu, Ceren
Aiello, Claudia
Apostolidis, Sokratis
Bar-Or, Amit
Bove, Riley
Espinoza, Diego
Brito, Sugeidy Ferreira
Jacobs, Dina
Kakara, Mihir
Onomichi, Kaho
Ricci, Adelle
Sabatino, Joseph
Walker, Elizabeth
Wherry, John
Zhang, LiLi
Zhu, Wen
De Jager, Philip
Farber, Donna L.
Wesley, Sarah Flanagan
Farber, Rebecca
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 315 - 316
[34] Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics
Megna, Matteo
Potestio, Luca
Battista, Teresa
Camela, Elisa
Genco, Lucia
Noto, Matteo
Fabbrocini, Gabriella
Martora, Fabrizio
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2022, 47 (12) : 2310 - 2312
[35] Clinical practice experience with nirmatrelvir/ritonavir as treatment for COVID-19 in patients with multiple sclerosis on immunosuppressive therapy
Diaz Perez, Carolina
Meca, Virginia
Aguirre, Clara
Del Rio Munoz, Beatriz
Vivancos, Jose
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1038 - 1038
[36] Evaluation of the durability of the immune humoral response to COVID-19 vaccines in patients with cancer undergoing treatment or who received a stem cell transplant (vol 8, pg 1053, 2022)
Khan, Q. J.
Bivona, C. R.
Martin, G. A.
JAMA ONCOLOGY, 2022, 8 (07) : 1073 - 1073
[37] Temporal evolution of humoral and T-cell specific immune response to COVID-19 mRNA vaccine in multiple sclerosis
Ruggieri, S.
Tortorella, C.
Aiello, A.
Farroni, C.
Haggiag, S.
Prosperini, L.
Cuzzi, G.
Salmi, A.
Quartuccio, M. E.
Vanin, V.
Altera, A. M. G.
Garbuglia, A. R.
Lapa, D.
Meschi, S.
Maffongelli, G.
Bartoli, T. Ascoli
Galgani, S.
Nicastri, E.
Gasperini, C.
Goletti, D.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 606 - 607
[38] Immune Response after COVID-19 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs
Mazziotti, Valentina
Crescenzo, Francesco
Tamanti, Agnese
Dapor, Caterina
Ziccardi, Stefano
Guandalini, Maddalena
Colombi, Annalisa
Camera, Valentina
Peloso, Angela
Pezzini, Francesco
Turano, Ermanna
Marastoni, Damiano
Calabrese, Massimiliano
BIOMEDICINES, 2022, 10 (12)
[39] Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy
Mackova, Jana
Hainz, Petr
Krystofova, Jitka
Roubalova, Katerina
Stastna-Markova, Marketa
Vanikova, Sarka
Musil, Jan
Vydra, Jan
Nemeckova, Sarka
LEUKEMIA RESEARCH, 2023, 130
[40] Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Achiron, Anat
Mandel, Mathilda
Dreyer-Alster, Sapir
Harari, Gil
Magalashvili, David
Sonis, Polina
Dolev, Mark
Menascu, Shay
Flechter, Shlomo
Falb, Rina
Gurevich, Michael
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14

← 1 2 3 4 5 →